SML2425
Manidipine hydrochloride
≥98% (HPLC)
别名:
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid hydrchloride, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester, 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrchloride, CV 4093 hydrchloride, CV-4093 hydrchloride, CV4093 hydrchloride, Franidipine hydrchloride, Manidipine 6300 hydrchloride
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C35H38N4O6 · xHCl
化学文摘社编号:
分子量:
610.70 (free base basis)
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear (warmed)
储存温度
2-8°C
生化/生理作用
Dihydropyridine class calcium channel blocker (CCB) that exerits its antihypertensive activity via targeting both L-type and T-type calcium channels.
Manidipine is a dihydropyridine class calcium channel blocker (CCB) that exerits its antihypertensive activity via targeting both L-type and T-type calcium channels. In contrary to other dihydropyridines and non-dihydropyridines that mainly act as L-type CCBs, Manidipine diminishes glomerular pressure and, consequently, albumin excretion via its action against T-type channels of efferent arterioles in addition to promoting afferent arteriole dilation by blocking L-type channels. Clinically, Manidipine is as effective in lowering blood pressure as other dihydropyridines, while only Manidipine significantly reduces albuminuria and insulin resistance with less adverse effects. In obese and hypertensive individuals, Manidipine is more effective than Lercanidipine in reducing insulin resistance, while Nifedipine treatment is reported to increase insulin desensitisation.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - STOT SE 3
靶器官
Central nervous system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
H Nakaya et al.
European journal of pharmacology, 146(1), 35-43 (1988-01-27)
The effects of CV-4093, a new dihydropyridine derivative, on isolated cardiovascular tissues were compared with those of several dihydropyridine and non-dihydropyridine calcium antagonists. CV-4093 effectively inhibited the contractions induced in canine femoral arteries by high [K+]0 and Bay K 8644
K Okabe et al.
The Journal of pharmacology and experimental therapeutics, 243(2), 703-710 (1987-11-01)
Effects of CV-4093, a newly synthesized dihydropiridine type of Ca antagonist, on membrane currents in enzymatically dispersed single smooth muscle cells of the rabbit main pulmonary artery were investigated using the single electrode voltage clamp method. Three types of membrane
Margarita Saiz-Satjes et al.
Future cardiology, 13(2), 143-151 (2016-11-26)
In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions. Factors associated with
A Nagaoka et al.
Japanese journal of pharmacology, 51(1), 25-35 (1989-09-01)
The effects of a new calcium antagonist, CV-4093.2HCl, on renal hemodynamics were examined in anesthetized and conscious spontaneously hypertensive rats (SHR). In the anesthetized rats, CV-4093.2HCl (5 and 10 micrograms/ kg, i.v.) showed a long-lasting hypotensive action, dilated renal vasculature
Margarita Saiz Satjes et al.
Future cardiology, 12(4), 435-447 (2016-05-26)
Renin-angiotensin system inhibitors should be considered as the first-line therapy in the treatment of patients with hypertension and diabetes. However, most of the diabetic subjects with hypertension require at least two drugs to achieve blood pressure targets. The ACCOMPLISH trial
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持